Jazz Pharmaceuticals

Pharma

ASCO: Roche, Jazz lung cancer win leaves room for improvement

Adding Zepzelca to Tecentriq led to a 27% reduction in the risk of death as maintenance treatment in first-line extensive-stage small cell lung cancer.

Angus Liu May 22, 2025 5:00pm

Jazz Pharma settles Xyrem antitrust claims for $145M

Apr 10, 2025 8:50am

Axsome's Sunosi scores in phase 3 ADHD trial

Mar 25, 2025 11:46am

Jazz reviewing M&A deal options of 'various sizes,' CFO says

Feb 26, 2025 11:08am

Jazz hunts for new CEO as longtime chief Cozadd eyes retirement

Dec 17, 2024 10:49am

Jazz's HER2 bispecific snags FDA nod to rival Enhertu

Nov 21, 2024 7:53am